Stocksigma LogoStocksigma Logo

Laurus Labs Reports Strong Q2 FY27 Results and Expands CDMO Capabilities

Laurus Labs reported strong Q2 FY27 financial results on 29th Oct'26, with revenue increasing 33% YoY to ₹2,206 Cr and net profit surging 126% YoY to ₹441

Laurus Labs Reports Strong Q2 FY27 Results and Expands CDMO Capabilities

Laurus Labs Ltd · Press Release · 29 Oct 2026, 9:06 pm

Laurus Labs Reports Strong Q2 FY27 Results and Expands CDMO Capabilities Laurus Labs reported strong Q2 FY27 financial results on 29th Oct'26, with revenue increasing 33% YoY to ₹2,206 Cr and net profit surging 126% YoY to ₹441 Cr. EBITDA rose 78% YoY to ₹762 Cr, with margins expanding 850 bps to 34.5%, driven by 75% YoY growth in the CDMO segment to ₹904 Cr. The company declared an interim dividend of ₹1.00 per share. Additionally, Laurus signed definitive agreements to acquire a 60% stake in Galenvs Sciences and 52% in SI &C Resins to enhance its oligonucleotide and peptide CDMO capabilities.

Original exchange filing (PDF)

More announcements from Laurus Labs Ltd

All Laurus Labs Ltd announcements